Mylan, Pfizer Announce Epinephrine Auto-injector Settlement Agreement With Teva

RELATED NEWS

Pfizer To Spin-off Rest Of Zoetis

Pfizer Intends To Split Off Its Remaining Interest In Zoetis - Quick Facts

Pfizer Stops Lymphoma Drug Late-Stage Trial Due To Ineffectiveness

Pfizer Cuts 2013 Outlook As First Quarter Results Miss Estimates

Pfizer Q1 13 Earnings Conference Call At 10:00 AM ET

Trade PFE now with

4/26/2012 8:07 AM ET

Mylan Inc. (MYL: Quote) said Meridian Medical Technologies, a Pfizer (PFE: Quote) subsidiary, has entered into a settlement agreement with Teva (TEVA: Quote) that will resolve pending patent litigation related to its abbreviated new drug application for a generic epinephrine auto-injector.

According to the settlement terms, Teva may launch a generic epinephrine auto-injector covered by its ANDA on June 22, 2015 or earlier under certain circumstances, subject to receipt of approval from the U.S. Food and Drug Administration. Teva currently does not have tentative approval from the FDA for its epinephrine auto-injector product.

Click here to receive FREE breaking news email alerts for Pfizer Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 79 Articles

Editors Pick

Modest Gain In Eurozone PMI Revives Recovery Hopes

An indicator of Eurozone's private sector activity improved more than expected in May, renewing hopes that the economy is inching towards a recovery. Nonetheless, the indicator remained in negative territory, signaling sharp deterioration in overall business activity. The composite output index rose to a three-month high of 47.7 in May from 46.9 in April.

China Manufacturing Contracts As New Orders Slump

China's manufacturing sector contracted for the first time in seven months in May amid poor demand, fueling concerns that the weakness in the economy may persist for some more time. The headline purchasing managers' index, an indicator of the health of the factory sector, fell to a seven-month low of 49.6 in May from 50.4 in April. Readings below 50 indicate contraction of the sector.

HP Profit Falls Yet Tops Estimates

Hewlett-Packard Co. said Wednesday after the markets closed that its second quarter profit fell 32% from last year, hurt by lower revenue and weaker margins amid a slump in PC sales. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast.